17:30 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
23:05 , Nov 5, 2018 |  BC Extra  |  Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
19:10 , Aug 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Patient sample and mouse studies suggest inhibiting NOX4 could help treat cancer. In samples from patients with squamous cell carcinoma of the head and neck (SCCHN), esophageal cancer, colorectal cancer, breast cancer or...
00:18 , Aug 8, 2017 |  BC Extra  |  Preclinical News

Researchers suggest inhibiting NOX4 could treat cancer

In a paper published in the Journal of the National Cancer Institute , researchers at the University of Southampton showed that inhibiting NADPH oxidase 4 (NOX4) in cancer-associated fibroblasts can abrogate the tumor-promoting function of...
18:23 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg GKT831 (formerly GKT137831) for 24 weeks in 102 patients with primary biliary cholangitis (PBC) and an inadequate response to ursodeoxycholic...
18:14 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Depression Mouse studies suggest inhibiting NOX1 could help treat depression. In two mouse models of depression, NOX1 knockdown decreased social avoidance and acute stress-induced immobility compared with normal expression. Next steps could include identifying...
21:07 , Dec 30, 2016 |  BC Week In Review  |  Company News

Genticel, Genkyotex deal

The companies will merge to form a publicly traded entity that plans to develop Genkyotex's pipeline of NADPH oxidase inhibitors to treat fibrotic diseases. Genkyotex’s shareholders will receive about 11.8 Genticel shares for each Genkyotex...
00:19 , Dec 23, 2016 |  BC Extra  |  Financial News

Genkyotex finds public path via Genticel merger

Genkyotex S.A. (Plan-les-Ouates, Switzerland) and Genticel S.A. (Euronext:GTCL) are merging to form a publicly traded entity that intends to develop Genkyotex's pipeline of NADPH oxidase inhibitors to treat fibrotic diseases. The Swiss biotech's shareholders will...
19:39 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; gastrointestinal

INDICATION: Inflammatory bowel disease (IBD); colitis Mouse studies suggest inhibiting NOX1 could help treat ulcerative colitis (UC). In a mouse model of ulcerative colitis, NOX1 knockout increased body weight and other markers of physical health...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

GKT137831: Phase II data

Top-line data from a double-blind, international Phase II trial in 155 Type II diabetics with diabetic nephropathy showed that twice-daily 100 mg oral GKT137831 for 6 weeks followed by a twice-daily 200 mg dose for...